Novartis announced that it has received an “approvable letter” from the US Food and Drug Administration (FDA) for Galvus? (vildagliptin), under review for US approval as a new once-daily oral treatment for patients with type 2 diabetes.
Three forms of garlic — including raw garlic and two types of commercial garlic supplements — did not significantly reduce low-density lipoprotein (LDL or “bad”) cholesterol during a six-month trial, according to results published in the Feb. 26 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
New research suggests that gene therapy is a safe treatment method to explore in patients whose lower limbs are at risk for amputation because of poor circulation caused by blocked blood vessels.
Psychological depression appears to contribute to worse medical outcomes for patients with heart failure, ranking it in importance with such risk factors as high cholesterol, hypertension, and even the ability of the heart to pump blood throughout the body.
CIHR-funded study explored the relationship between use of antidepressants and level of alcohol consumption, examining whether using antidepressants affected the link between depression and level of alcohol consumption.
Dartmouth/VA researchers show that adding CRP testing to routine assessments would increase the number of Americans eligible for cholesterol-lowering treatment by about two million if used judiciously, and by over 25 million if used broadly — with most of these people being at low risk for heart attacks or heart disease.
Many doctors should change the way they prescribe pain relievers for chronic pain in patients with or at risk for heart disease based on accumulated evidence that nonsteroidal anti-inflammatory drugs (NSAIDs), with the exception of aspirin, increase risk for heart attack and stroke, according to an American Heart Association statement published in Circulation: Journal of the American Heart Association.
The future of cancer detection and treatment may be in gold nanoparticles ? tiny pieces of gold so small they cannot be seen by the naked eye.
Cancer cells differ from normal cells in, among other things, the way they divide. When a normal cell complies with a signal telling it to divide, it also begins to activate a “braking system” that eventually stops cell division and returns the cell to a resting state.
Bristol-Myers Squibb Company (NYSE: BMY) and Adnexus(TM) Therapeutics today announced a worldwide strategic alliance to discover, develop and commercialize Adnectin-based therapeutics for important oncology-related targets.